Associated Genetic Biomarkers
Fli-1 proto-oncogene, ETS transcription factor (FLI1) is a gene that encodes a protein that functions as an ETS DNA-binding domain containing transcription factor. Fusions, missense mutations, nonsense mutations, silent mutations, and frameshift deletions are observed in cancers such as intestinal cancer, parathyroid cancer, and skin cancer.
FLI1 is altered in 0.26% of all cancers with Ewing sarcoma, lung adenocarcinoma, prostate adenocarcinoma, sarcoma, NOS, and soft tissue neoplasm having the greatest prevalence of alterations .
The most common alterations in FLI1 are FLI1-EWSR1 Fusion (0.19%), FLI1 S89N (0.28%), FLI1 A25G (0.22%), FLI1 A297T (12.50%), and FLI1 D14N (0.26%) .
FLI1 status serves as an inclusion eligibility criteria in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials that contain FLI1 status as an inclusion criterion, 1 is phase 1 (1 open) and 1 is phase 2 (1 open).
The most frequent alteration to serve as an inclusion eligibility criterion is EWSR1-FLI1 Fusion .
Significance of FLI1 in Diseases
Ewing Sarcoma +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.